Advertisement
Home 2022

Archives

HTN Meds Tied to Lower Mortality After Pancreatic Cancer Diagnosis

DDW: Gallstone Disease May Predict Pancreatic Cancer Incidence

0

Gallstone presentation may be a missed opportunity for earlier diagnosis

B 5/13 -- Heavy Antibiotic Use Tied to Development of Crohn's

DDW: Antibiotics Up Risk of Older-Onset Inflammatory Bowel Disease

0

Findings regardless of antibiotic class and with a dose-response relationship

AI Applied to Apple Watch ECG Can ID Ejection Fraction ≤40 Percent

0

Artificial intelligence algorithm applied to watch single-lead ECG identified 13 of 16 patients with left ventricular dysfunction

Early Rhythm Control Key in A-Fib and Heart Failure

Subcutaneous Implantable Defibrillators Cut Lead-Related Complications

0

Risk for major lead-related complications much lower with subcutaneous ICD versus transvenous ICD

Throat examination

Adding Tislelizumab to Chemo Slows Advanced Nasopharyngeal Cancer

0

Progression-free survival prolonged with tislelizumab + chemotherapy versus chemotherapy alone in recurrent/metastatic NPC

AACR: Novel COVID-19 Vaccine Aimed at Immunocompromised Patients

0

CoVac-1, a peptide vaccine, induces T-cell immune responses in those with B-cell deficiencies, particularly leukemia and lymphoma patients

AACR: Resistance Mechanisms to CAR-T Cell Therapy ID’d in ALL

0

Mechanisms of resistance detectable prior to treatment and include hypermethylation of PCR2 targets in embryonic and cancer stem cells

Human Respiratory System Anatomy

AACR: Adding Nivolumab to Neoadjuvant Chemo Slows Resectable NSCLC

0

Event-free survival prolonged and percentage of patients with a pathological complete response higher with addition of nivolumab

ACC: Infected CV Implantable Electronic Devices Often Not Removed

0

Although extraction within six days is linked to lower mortality, hardware not removed in 78.9 percent of patients with infected devices

ACC: Mavacamten Cuts Need for Surgery in Hypertrophic Cardiomyopathy

0

After 16 weeks, 76.8 and 17.9 percent in the placebo and mavacamten groups, respectively, decided to proceed with or were eligible for surgery